| Type of cancer | Cell line | Dose/concentration | Molecular targets | References |
| Leukemia | HL-60 | 6 ± 1 µM | Bax↑, Bcl-2↓, caspase-3/-7Act, JNK/SAPK┴, and ERK 1/2┴ | [15] | Hepatocellular | HepG2, Huh-7, and H22 | — | HK2┴ and miR-125b↑ | [150] | Skin | HaCaT, A375P, and SK-MEL-2 | 50 and 100 M/mL | p38 MAPK↓, phospho-MSK1↓, γ-H2AX↓, caspase-9/-3Act, BaxAct, PARP cleavage, cyclin D1↓, Mcl-1↓, and SOX10┴ | [151, 152] | Lung | A549, H1299, H226, H838, H23, H1437, H125, H2009, and H2087 | 5, 40 µg/mL (A549) and 20 µg/mL (H1299) | Bax:Bcl-2↑, caspase-9/-3↑, p-IKK-β↓, NF-κB p65┴, TNF-α┴, ERK-1/2┴, JNK↑, PI3K/Akt┴, DDH┴, DRP-1↓, pro-caspase-3/-8↑, and Bax↑ | [145, 153] | Breast | ZR-75-1, T47D, BT20, MCF-1, and MCF-7 | — | DDH┴, DRP-1↓, pro-caspase-3/-8↑, and Bax↑ | [153] | Gastric | AGS, SC-M1, NUGC-1, NUGC-3, and KOTA-III | — | DDH┴, DRP-1↓ pro-caspase-3/-8↑, and Bax↑ | [153] |
|
|